Daniel E Spratt1, Julio Arevalo-Perez2, Jonathan E Leeman3, Naamit K Gerber3, Michael Folkert4, Neil K Taunk3, Kaled M Alektiar3, Sasan Karimi2, John K Lyo2, William D Tap5, Mark H Bilsky6, Ilya Laufer6, Yoshiya Yamada3, Joseph R Osborne2. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA; Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109. Electronic address: sprattda@med.umich.edu. 2. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA; Department of Radiation Oncology, UT Southwestern, 2001 Inwood Rd, Dallas, TX 75235. 5. Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA. 6. Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Abstract
BACKGROUND CONTEXT: Recent advances in image guidance and stereotactic body radiotherapy (SBRT) have resulted in unprecedented local control for spinal metastases of all histologies. However, little is known about early imaging biomarkers of local control. PURPOSE: This study aimed to identify early magnetic resonance imaging (MRI) biomarkers to predict local control after SBRT for patients with sarcoma spine metastases. STUDY DESIGN/ SETTING: This study used a retrospective case series at a large tertiary cancer center. PATIENT SAMPLE: From 2011 to 2014, 9 consecutive patients with 12 metastatic sarcoma lesions to the spine were treated with SBRT and underwent evaluation with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) both pre- and post-SBRT. OUTCOME MEASURE: Changes in perfusion metrics, including the wash-in rate constant (Ktrans), plasma volume (Vp), composite multiparametric magnetic resonance imaging (mpMRI) score, bi-dimensional tumor size, and a graded response assessment were performed and correlated to local control. METHODS: All measurements were independent and blinded by two neuroradiologists. R2 statistics were performed to document correlation, and two-tailed t tests were used to compare groups. p<.05 was deemed statistically significant. RESULTS: The median time from SBRT until posttreatment MRI was 57 days. Local failure developed in one lesion (8.3%) 10 months after SBRT. The Vp mean, Ktrans mean, Vp max, and Ktrans max were significantly decreased post-SBRT as compared with pre-SBRT (58.7%, 63.2%, 59.0%, and 55.2%; all p-values <.05). Bi-dimensional tumor measurements demonstrated an average increase in size across the cohort, and 50%, 25%, and 25% of the treated lesions demonstrated features of "worsening," "no change," or "improvement," respectively, by both radiologists' graded impressions. There was good inter-reader reliability for both size and subjective disease response scores (R2=0.84). The mpMRI score had 100% accuracy in predicting local control at time of last follow-up. There was no apparent correlation with size changes compared with the mpMRI score change post-SBRT (R2=0.026). CONCLUSIONS: We report the first analysis on the utility of DCE-MRI for metastatic sarcoma spine metastases treated with SBRT. We demonstrate that early assessment at 2 months post-SBRT using size and subjective neuroradiology impressions is insufficient to judge ultimate disease progression, and that a combination of perfusion parameters provides excellent correlation to local control.
BACKGROUND CONTEXT: Recent advances in image guidance and stereotactic body radiotherapy (SBRT) have resulted in unprecedented local control for spinal metastases of all histologies. However, little is known about early imaging biomarkers of local control. PURPOSE: This study aimed to identify early magnetic resonance imaging (MRI) biomarkers to predict local control after SBRT for patients with sarcoma spine metastases. STUDY DESIGN/ SETTING: This study used a retrospective case series at a large tertiary cancer center. PATIENT SAMPLE: From 2011 to 2014, 9 consecutive patients with 12 metastatic sarcoma lesions to the spine were treated with SBRT and underwent evaluation with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) both pre- and post-SBRT. OUTCOME MEASURE: Changes in perfusion metrics, including the wash-in rate constant (Ktrans), plasma volume (Vp), composite multiparametric magnetic resonance imaging (mpMRI) score, bi-dimensional tumor size, and a graded response assessment were performed and correlated to local control. METHODS: All measurements were independent and blinded by two neuroradiologists. R2 statistics were performed to document correlation, and two-tailed t tests were used to compare groups. p<.05 was deemed statistically significant. RESULTS: The median time from SBRT until posttreatment MRI was 57 days. Local failure developed in one lesion (8.3%) 10 months after SBRT. The Vp mean, Ktrans mean, Vp max, and Ktrans max were significantly decreased post-SBRT as compared with pre-SBRT (58.7%, 63.2%, 59.0%, and 55.2%; all p-values <.05). Bi-dimensional tumor measurements demonstrated an average increase in size across the cohort, and 50%, 25%, and 25% of the treated lesions demonstrated features of "worsening," "no change," or "improvement," respectively, by both radiologists' graded impressions. There was good inter-reader reliability for both size and subjective disease response scores (R2=0.84). The mpMRI score had 100% accuracy in predicting local control at time of last follow-up. There was no apparent correlation with size changes compared with the mpMRI score change post-SBRT (R2=0.026). CONCLUSIONS: We report the first analysis on the utility of DCE-MRI for metastatic sarcoma spine metastases treated with SBRT. We demonstrate that early assessment at 2 months post-SBRT using size and subjective neuroradiology impressions is insufficient to judge ultimate disease progression, and that a combination of perfusion parameters provides excellent correlation to local control.
Authors: Yoshiya Yamada; Mark H Bilsky; D Michael Lovelock; Ennapadam S Venkatraman; Sean Toner; Jared Johnson; Joan Zatcky; Michael J Zelefsky; Zvi Fuks Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-30 Impact factor: 7.038
Authors: M Verheij; R Bose; X H Lin; B Yao; W D Jarvis; S Grant; M J Birrer; E Szabo; L I Zon; J M Kyriakis; A Haimovitz-Friedman; Z Fuks; R N Kolesnick Journal: Nature Date: 1996-03-07 Impact factor: 49.962
Authors: Charles G Fisher; Christian P DiPaola; Timothy C Ryken; Mark H Bilsky; Christopher I Shaffrey; Sigurd H Berven; James S Harrop; Michael G Fehlings; Stefano Boriani; Dean Chou; Meic H Schmidt; David W Polly; Roberto Biagini; Shane Burch; Mark B Dekutoski; Aruna Ganju; Peter C Gerszten; Ziya L Gokaslan; Michael W Groff; Norbert J Liebsch; Ehud Mendel; Scott H Okuno; Shreyaskumar Patel; Laurence D Rhines; Peter S Rose; Daniel M Sciubba; Narayan Sundaresan; Katsuro Tomita; Peter P Varga; Luiz R Vialle; Frank D Vrionis; Yoshiya Yamada; Daryl R Fourney Journal: Spine (Phila Pa 1976) Date: 2010-10-15 Impact factor: 3.468
Authors: Marcelo V R Cunha; Ameen Al-Omair; Eshetu G Atenafu; Giuseppina Laura Masucci; Daniel Letourneau; Renee Korol; Eugene Yu; Peter Howard; Fiona Lochray; Leodante B da Costa; Michael G Fehlings; Arjun Sahgal Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-01 Impact factor: 7.038
Authors: Jonathan H Lee; Jonathan P Dyke; Douglas Ballon; Deborah McK Ciombor; Glenn Tung; Roy K Aaron Journal: Orthop Clin North Am Date: 2009-04 Impact factor: 2.472
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: Amani Arthur; Edward W Johnston; Jessica M Winfield; Matthew D Blackledge; Robin L Jones; Paul H Huang; Christina Messiou Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738
Authors: Kiran A Kumar; Kyung K Peck; Sasan Karimi; Eric Lis; Andrei I Holodny; Mark H Bilsky; Yoshiya Yamada Journal: Technol Cancer Res Treat Date: 2017-04-28
Authors: Hayley M Reynolds; Bimal K Parameswaran; Mary E Finnegan; Diana Roettger; Eddie Lau; Tomas Kron; Mark Shaw; Sarat Chander; Shankar Siva Journal: PLoS One Date: 2018-08-16 Impact factor: 3.240
Authors: Matthew Mouawad; Heather Biernaski; Muriel Brackstone; Michael Lock; Brian Yaremko; Olga Shmuilovich; Anat Kornecki; Ilanit Ben Nachum; Giulio Muscedere; Kalan Lynn; Frank S Prato; R Terry Thompson; Stewart Gaede; Neil Gelman Journal: Clin Transl Radiat Oncol Date: 2019-12-25